Kimberly Westrich, MA, of the National Pharmaceutical Council, explained how she envisions value assessment tools to be used in the US health care system in coming years.
CMS Must Obtain Clinician Input Today To Prevent Part D Access Barriers Tomorrow healthaffairs.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healthaffairs.org Daily Mail and Mail on Sunday newspapers.
ICER has identified 8 drugs with price increases that are not supported by new clinical evidence, resulting in $1.3 billion in additional costs for U.S. payers.
How The IRA Could Delay Pharmaceutical Launches, Reduce Indications, And Chill Evidence Generation healthaffairs.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healthaffairs.org Daily Mail and Mail on Sunday newspapers.